FDA Tweaks Medical Device Standards List—Number 066 Edition
Published Date: 8/24/2026
Notice
Summary
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
FDA publishes Recognition List 066
The FDA published "Modifications to the List of Recognized Standards, Recognition List Number: 066," effective August 24, 2026. The notice is intended to assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
Many standards withdrawn and replaced
The notice lists multiple consensus standards that FDA is withdrawing and replacing with newer versions (for example, ISO 10079-1; ISO 10993-1; ISO 10993-12; ISO 5840 series; IEC 60601-2-2; ASTM F2942-25 and others), as shown in Table 1. These modifications are incorporated under Recognition List Number: 066 and are applicable August 24, 2026.
New recognized standards added
Table 2 of the notice lists new entries added to FDA's list of recognized consensus standards (Recognition List Number: 066), including many dental ANSI/ADA standards (e.g., ANSI/ADA 113-2015, 126-2015, 135-2015), ISO 7176-31 (Lithium-ion battery systems for powered wheelchairs, edition 2023-05), IEC 80601-2-26 (electroencephalographs, edition 2024-03), and IEEE Std 1752.1-2021. These newly recognized standards are part of the modifications adopted under Recognition List Number: 066.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
Previous / Next Documents
Previous: 2026-17226, Agency Information Collection Activities; Proposed Collection; Comment Request; Extension: Form N-54A
Next: 2026-17233, Proposed Collection; Comment Request
The Navy wants to keep collecting feedback through its Quarterly Brand Opinion Survey and is asking the public to share thoughts on how to make it better and easier to use. This helps the Navy improve how it communicates with people. If you have ideas or concerns, you’ve got until October 23, 2026, to speak up—no cost to you, just your opinion!